Reduced expression of p53 and p21waf1/cip1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil

Anticancer Research

Volumn 22, Issue 6 A, 2002, Pages 3197-3204

  Johnson, Korey R ^a   Fan, Weimin ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

5 fluorouracil; Apoptosis; Breast cancer; Mitotic arrest; P21WAF1 CIP1; P53; Paclitaxel

Indexed keywords

COMPLEMENTARY DNA; FLUOROURACIL; PACLITAXEL; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, ANTISENSE; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; PACLITAXEL; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036870714     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Wani MC, Taylor HL, Wall ME et al: Plant antitumor agents: VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 23-25, 1971.
2. Holmes FA, Walter RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
3. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB and Paietta E: Phase I clinical and pharmicokinetics study of taxol. Cancer Res 47: 2486-2493, 1987.
4. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 22: 665-667, 1979.
5. Kumar N: Taxol induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435-10441, 1981.
6. Rowinsky EK, Donehower RC, Jones RJ and Tucker RW: Microtubule changes and cyotoxicity in leukemia cell lines treated with taxol. Cancer Res 48: 4093-4100, 1988.
7. Horwitz SB: Mechanism of action of Taxol. Trends Pharmacol Sci 13: 134-136, 1992.
8. Woods CM, Zhu J, McQueney PA, Bollag D and Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent pathway. Mol Med 1: 506-526, 1995.
9. Kung AL, Zetterberg A, Sherwood AW and Schimke RT: Cytotoxic effects of cell cycle specific agents: a result of cell cycle perturbation. Cancer Res 50: 7307-7314, 1990.
10. Donaldson KL, Goolsby G, Kiener PA and Whal AF: Activation of p34cdc2 coincident with Taxol-induced apoptosis. Cell Growth & Differ 5: 1041-1050, 1994.
11. Rowinsky E K, Cazenvae LA and Donehower RC: Taxol: a novel investigational antinmicrotubule agent. J Natl Inst Cancer 82: 1247-1259, 1990.
12. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME and Huang Y: Paclitaxel induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells, Leukemia 7: 563-568, 1993
13. Cheng L, Roghunathan K, Priest DG, Willingham MC, Norris JS and Fan W: Characterizations of paclitaxel-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 2: 249-257, 1995
14. Fan W: Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57: 1215-1221, 1999.
15. Liu Y, Bhalla K, Hill C and Priest DG: Evidence for invovlement of tyrosine phosphorylation in paclitaxel-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 48: 1265-1272, 1995.
16. Klassen U, Wilke H, Pari CP, Strumberg D, Harstrick A, Eberhardt W, Becher R, Diergarten K and Seeber S: Phase I/II study with paclitaxel in combination with weekely high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. Semin Oncol 22(6 Suppl. 14): 7-11, 1995.
17. Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL and Johnson DH: Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience. Sem Oncol 23(1 suppl 1): 48-52, 1996.
18. Vokes EE, Stupp R, Haraf D, Moran W, Malone D, Wenig B, Sweeney P and Weichselbaum RR: Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol 22(3 suppl 6): 47-52, 1995.
19. Ajani JA, Ilson DH and Kelsen DP: The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 22(5 Suppl 12): 46-50; discussion 51-3, 1995.
20. Johnson KR, Wang L, Miller MC III, Willingham MC and Fan W: 5-fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res 3: 1739-1745, 1997.
21. Johnson KR, Young KK and Fan W: Antagonistic interplay between antimitotic and G1/S arresting agents observed in experimental combination therapy. Clin Cancer Res 5: 2559-2565, 1999.
22. Nojima H: Cell cycle checkpoints, chromosome stability and the progression of cancer. Human Cell 10(4): 221-30, 1997.
23. Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312, 1999.
24. Agarwal ML, Taylor WR, Chernov OB and Stark GR: The p53 network. J Biol Chem 273(1): 1-4, 1998.
25. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75(4): 817-825, 1993.
26. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y et al.: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54(5): 1169-74, 1994.
27. Di Leonardo A, Linke SP, Clarkin K and Wahl GM: DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblast. Genes & Dev 8: 2540-2551, 1994.
28. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1500, 1998.
29. Whal AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW and Galloway DA: Loss of normal p53 confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996.
30. Trielli MO, Andreassen PR, Lacroix FB and Margolis RL: Differential taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Biol Chem 135: 689-700, 1996.
31. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M and Broggini M: p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57: 870-874, 1997.
32. Fan S, Cherney B, Reinhold W, Rucker K and O'Conner PM: Disruption of p53 function in immortalized human cells does not affect cell survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4: 1047-1054, 1998.
33. Fan W, Cheng L, Norris JS and Willingham MC: Glucocorticoids selectively inhibit taxol-induced apoptosis in a human breast cancer cell line. Cell Pharmacol 3: 435-440, 1996.
34. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
35. Fan W, Johnson KR and Miller MC III: In vitro evaluation of combination chemotherapy against human tumor cells (Review). Oncology Reports 5: 1035-1042, 1998.
36. Zeng S, Chen YZ, Johnson KR. and Fan W: In vitro evaluation of sequential-dependent combination between docetaxel and doxorubicin in human tumor cells. Clin Cancer Res 6: 3766-3773, 2000
37. Huang Y, Johnson RK, Norris JS and Fan W: Nuclear factor-κB/I-κB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60: 4426-4432, 2000.
38. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
39. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y and Adachi K: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704-710, 1996.
40. Grem JL, Nguyen D, Monahan BP, Kao V and Geoffroy FJ: Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 58: 477-486, 1999.
41. Manfredi JJ and Horwitz SB: Paclitaxel: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-125, 1984.
42. Barboule N, Chadebech P, Baldin V, Vidal S and Valette A: Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15: 2867-2875, 1997.
43. Stewart ZA, Mays D and Pietenpol JA: Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res 59: 3831-3837, 1999.